Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked first in patient centricity, integrity, ease of relations and transparency in pricing by patient groups who worked with the company around
DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcrip.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the third annual global innovation challenge, The Horizon Prize, powered by MIT Solve. Each year, the Horizon Prize poses a challenge
DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the third annual global innovation challenge, The Horizon Prize, powered by MIT Solve.Each year, the Horizon Prize poses a challenge question, asking entrepreneurs and innovators worldwide to think creatively to solve a re.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of Fortune's 100 Best Companies to Work For for the third consecutive year. "We are proud to be named to the Fortune